Although symptoms can range in severity, all patients with XLMTM face substantial challenges throughout their lives. Most have severe XLMTM and require intensive, lifelong medical interventions and caregiver support.

Severe XLMTM can be devastating for patients and caregivers. Patients with severe XLMTM experience substantial challenges from birth.

At birth:

Healthcare requirements1

  • Patients with severe XLMTM typically present with profound muscle weakness, hypotonia, and respiratory distress. 
  • These patients require immediate medical intervention and potentially lengthy neonatal intensive care unit (NICU) stays.


Sadly, even with respiratory support, nearly half of patients with XLMTM are likely to die by 18 months of age—mainly from respiratory failure or related complications, such as pneumonia or ventilator-related accidents.3,5

During infancy and throughout childhood:

Healthcare requirements

  • Daily intensive medical intervention2,6
  • Ongoing respiratory support, with up to 24 hours of continuous invasive mechanical ventilation1,2,4,7
  • Dependence on gastrostomy tube feeding1,5,7,8
  • Wheelchair assistance for ambulation; patients with severe XLMTM do not achieve independent ambulation1
  • Frequent need for speech therapy, training in sign language, and communication-assist devices1,9
  • Lifelong supportive care from a multidisciplinary care team and their family 1,9,10

Quality of life

  • Missed motor milestones, such as normal head control, sitting, standing, and walking3,7,8,11
  • Difficulties with speech, articulation, and communication, especially for those dependent on a ventilator1,5,9
  • Potential limitations on social activities5,8

Milder XLMTM presentations are not as debilitating but still impactful. Patients with moderate to mild XLMTM present with less profound symptoms but still experience meaningful effects throughout their lives.1,8

At birth:

  • Patients with milder XLMTM typically present with hypotonia and mild/moderate weakness.6,8

During infancy and throughout childhood:

  • Patients achieve independent ambulation, although weakness and gait abnormalities may be apparent.1,6
  • They may not need respiratory or ventilator support until they are older (primarily at night) or require transient ventilatory support.1,6,8
  • Most children still require feeding assistance or gastrostomy tubes.1,6,8

To adulthood:

Patients with moderate or mild XLMTM may live into adulthood.1,8

The physical demands, expenses, and emotional stressors of caring for a medically fragile patient with XLMTM can be hard for caregivers and detrimental to quality of life.12 Families and caregivers of patients with XLMTM may experience some or all of these challenges.

Productivity loss12*

  • ~26 to 32 missed work days in a year

Financial challenges12*

  • Out-of-pocket costs of nursing or equipment not covered by insurance
  • Need for secondary and/or self-employment insurance
  • Limited or no government assistance
  • High insurance costs (premiums and deductibles)

Emotional and physical impacts12*

  • Feelings of helplessness and guilt over physical limitations
  • Fear for the patient’s survival
  • Feelings of isolation and loneliness
  • Sleep deprivation
  • Wear and tear from physical demands and the intensity of caregiving

*Results from a quantitative, web-based survey of 22 US caregivers of individuals with XLMTM conducted between November 19, 2019, and January 23, 2020. The survey was co-designed with patient advocacy leaders.12

Early recognition of XLMTM symptoms and accurate diagnosis are essential for effective disease management.

References

 

1. Dowling JJ, Lawlor MW, Das S. X-linked myotubular myopathy. In: Adam MP, Bick S, Mirzaa GM, et al., eds. GeneReviews® [Internet]. Updated August 23, 2018. Accessed November 17, 2025. https://www.nchi.nlm.nih.gov/books/NBK1432/ 2. Sacks NC, Healey BE, Cyr PL, et al. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims. J Manag Care Spec Pharm. 2021;27(8):1019-1026. doi: 10.18553/jmcp.2021.20501 3. McEntagart M, Parsons G, Buj-Bello A, et al. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord. 2002;12(10)·939-946 doi:101016/ s0960-8966(02)00153-0 4. Graham RJ, Muntoni F, Hughes I, et al. Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis. Arch Dis Child. 2020;105(4):332-338. doi:10.1136/archdischild-2019-317910 5. Beggs AH, Byrne BJ, De Chastonay S, et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy. The RECENSUS study. Muscle Nerve. 2018;57(4):550-560. doi:10.1002/mus.26018 6. Lawlor MW, Dowling JJ. X-linked myotubular myopathy. Neuromuscul Disord. 2021;31(10).1004-1012. doi:10.1016/j.nmd.2021.08.003 7. Dowling JJ, Müller-Felber W, Smith BK, et al. INCEPTUS natural history, run-in study for gene replacement clinical trial in X-linked myotubular myopathy. J Neuromuscul Dis. 2022;9(4):503-516. doi: 10.3233/JND-210781 8. Annoussamy M, Lilien C. Gidaro T, et al. X-linked myotubular myopathy: A prospective international natural history study. Neurology. 2019;92(16):e1852-e1867. doi:10.1212/WNL.0000000000007319 9. Wang CH, Dowling JJ, North K, et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol. 2012:27(3):363-382. doi:10.1177/0883073812436605 10. Graham RJ, Darras BT, Haselkorn T, et al. Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States. Orphanet J Rare Dis. 2023;18(1):138. doi: 10.1186/s13023-023-02733-2 11. Amburgey K, Tsuchiya E, de Chastonay S, et al. A natural history study of X-linked myotubular myopathy. Neurology. 2017;89(13):1355-1364. doi:10.1212/WNL.0000000000004415 12. Duong T, Haselkorn T, Miller B, et al. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis. 2025;20(1):224. doi:10.1186/s13023-025-03583-w